Human Relaxin-2

Peptide

Human Relaxin-2 is retained as a catalog identity with independently verified primary-literature context. No qualified exposure model, dose recommendation, efficacy claim, or safety claim is provided.

Pharmacokinetic model

A route-level PK model for human relaxin-2 is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.

Key facts

Category: Peptide
Suggested cadence: once daily

Research behind this entry

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF, Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M, RELAXin in Acute Heart Failure (RELAX-AHF) Investigators · Lancet (London, England), 2013 DOI
This citation reports a human clinical study involving Human Relaxin-2. It does not establish a qualified human dose, safety profile, efficacy claim, or pharmacokinetic route for this catalog record.

1 published study referenced in the app, each with a plain-language summary.